Export

Sodium stibogluconate
Essential medicine status
Section:
6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.2. Antileishmaniasis medicines
ATC codes: P01CB02
EMLc
Indication
Mucocutaneous leishmaniasis ICD11 code: 1F54.2
INN
Sodium stibogluconate
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Formulations
Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
EML status history
First added in 1977 (TRS 615)
Changed in 1979 (TRS 641)
Changed in 1984 (TRS 722)
Removed in 1989 (TRS 796)
Added in 2007 (TRS 950)
Changed in 2009 (TRS 958)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Sodium stibogluconate
DrugBank
Sodium stibogluconate
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule